Ranbaxy to market new Daiichi Sankyo antibiotic in Romania

Newsroom 22/07/2010 | 13:51

Pharmaceutical companies Daiichi Sankyo and Ranbaxy announced plans to leverage Ranbaxy’s presence in Romania to market antibiotic Tavanic (levofloxacin), a synthetic antibacterial agent used to treat a broad range of infections.

The decision came after which Daiichi Sankyo and Sanofi-Aventis have agreed early this year to transfer the marketing rights of Tavanic in Romania and South Africa from Sanofi-Aventis to Ranbaxy.

Daiichi Sankyo worked with Sanofi-Aventis since 1993 for the manufacture and sales of levofloxacin covering Europe, Africa, Middle East, South America and part of Asia.

The transfer is expected to be effective in August 2010 for Romania. Commercialization of Tavanic by Sanofi-Aventis remains unchanged in the other territories. 

 

Dana Ciuraru

BR Magazine | Latest Issue

Download PDF or read online: November 2022 Issue | Business Review Magazine

The November 2022 issue of Business Review Magazine is now available in digital format, featuring the main cover story titled “Samsung Remains Top Consumer Tech Provider on Romanian Market.” Read
Newsroom | 29/11/2022 | 10:17

    You will receive a download link for the latest issue of Business Review Magazine in PDF format, based on the completion of the form below.

    I agree with the Privacy policy of business-review.eu
    I agree with the storage and handling of my data by business-review.eu
    Advertisement Advertisement
    Close ×

    We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

    Accept & continue